www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_3rd_Annual_Citi_Biotech_Day_774969 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs ...http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_3rd_Annual_Citi_Biotech_Day_774969http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_NewsMakers_in_the_Biotech_Industry_Conference_775224 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs ...http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_NewsMakers_in_the_Biotech_Industry_Conference_775224http://www.finanzen.net/nachricht/Allos_Therapeutics_Reports_2008_Second_Quarter_Results_765522Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the second quarter of 2008. For the three months ended June 30, 2008, the Company reported a net loss of $11.8 million, or ($0.16) per share. This compares to a net loss of $10.4 million, ...http://www.finanzen.net/nachricht/Allos_Therapeutics_Reports_2008_Second_Quarter_Results_765522http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_Bank_of_America_2008_Specialty_Pharmaceuticals_Conference_757313Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that members of the Company’s senior management ...http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_Bank_of_America_2008_Specialty_Pharmaceuticals_Conference_757313http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Report_Second_Quarter_2008_Results_on_August_5_2008_756630Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it will report second quarter 2008 results on Tuesday, August 5, 2008, after the U.S. financial markets close. Paul L. Berns, President and Chief Executive Officer, ...http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Report_Second_Quarter_2008_Results_on_August_5_2008_756630http://www.finanzen.net/nachricht/Allos_Therapeutics_Initiates_Phase_2_Study_of_PDX_in_Patients_with_Advanced_or_Metastatic_Relapsed_Transitional_Cell_Carcinoma_of_the_Urinary_Bladder_755949Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the initiation of patient enrollment in a Phase 2, open-label, single-arm, multi-center study of PDX (pralatrexate) in patients with advanced or metastatic relapsed transitional ...http://www.finanzen.net/nachricht/Allos_Therapeutics_Initiates_Phase_2_Study_of_PDX_in_Patients_with_Advanced_or_Metastatic_Relapsed_Transitional_Cell_Carcinoma_of_the_Urinary_Bladder_755949http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_Collins_Stewart_Fourth_Annual_Growth_Conference_749433Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that members of the Company’s senior management ...http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_Collins_Stewart_Fourth_Annual_Growth_Conference_749433http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_Seventh_Annual_Needham__Company_LLC_Biotechnology_and_Medical_Technology_Conference_737767Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that members of the Company’s senior management ...http://www.finanzen.net/nachricht/Allos_Therapeutics_to_Present_at_the_Seventh_Annual_Needham__Company_LLC_Biotechnology_and_Medical_Technology_Conference_737767http://www.finanzen.net/nachricht/Allos_Therapeutics_Announces_Interim_Data_from_Phase_1_Study_of_PDX_in_Patients_with_Relapsed_or_Refractory_Cutaneous_T_Cell_Lymphoma_737497Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the presentation of interim data from its Phase 1 study of PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous ...http://www.finanzen.net/nachricht/Allos_Therapeutics_Announces_Interim_Data_from_Phase_1_Study_of_PDX_in_Patients_with_Relapsed_or_Refractory_Cutaneous_T_Cell_Lymphoma_737497http://www.finanzen.net/nachricht/Allos_Therapeutics_Announces_Closing_of_Public_Common_Stock_Offering_733646Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today the closing of its previously announced underwritten public offering of 12,420,000 shares of newly issued common stock at a public offering price of $5.64 per share. The number ...http://www.finanzen.net/nachricht/Allos_Therapeutics_Announces_Closing_of_Public_Common_Stock_Offering_733646